In conclusion, we applied immunohistochemistry to analyze HHLA2 expression pattern in melanoma, and evaluated the influence of HHLA2 expression levels on the efficacy of immunotherapy in ICB-treated patients with advanced or unresectable melanoma. This evidence concerns the gene HHLA2 and melanoma.